{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:42:57Z","timestamp":1789177377307,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T00:00:00Z","timestamp":1644278400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp &amp; Dohme Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.cmi.2022.01.029","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T21:33:27Z","timestamp":1644442407000},"page":"1003-1009","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Posaconazole bioavailability of the solid oral tablet is reduced during severe intestinal mucositis"],"prefix":"10.1016","volume":"28","author":[{"given":"Anouk M.E.","family":"Jansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eline W.","family":"Muilwijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter J.F.M.","family":"van der Velden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan A.","family":"Maertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robina","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Colbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Verweij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"ter Heine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.A.","family":"Blijlevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger J.M.","family":"Br\u00fcggemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2022.01.029_bib1","first-page":"3221","article-title":"European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia","volume":"73","author":"Maertens","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2022.01.029_bib2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.01.029_bib3","first-page":"2933","article-title":"Biomarkers and non-invasive tests for gastrointestinal mucositis","volume":"25","author":"Kuiken","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.cmi.2022.01.029_bib4","doi-asserted-by":"crossref","first-page":"6879","DOI":"10.1128\/AAC.03777-14","article-title":"Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis","volume":"58","author":"Dolton","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2022.01.029_bib5","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ijantimicag.2010.11.021","article-title":"A\u00a0post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis","volume":"37","author":"Bryant","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2022.01.029_bib6","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/FTD.0b013e31824d135c","article-title":"Posaconazole treatment in hematology patients: a pilot study of therapeutic drug monitoring","volume":"34","author":"Crombag","year":"2012","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.cmi.2022.01.029_bib7","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1185\/03007990903485056","article-title":"Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome","volume":"26","author":"AbuTarif","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.cmi.2022.01.029_bib8","series-title":"Noxafil-H-C-610-X-0028","author":"EMA","year":"2014"},{"key":"10.1016\/j.cmi.2022.01.029_bib9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.drup.2014.06.001","article-title":"The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside","volume":"17","author":"Seyedmousavi","year":"2014","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.cmi.2022.01.029_bib10","unstructured":"European Conference on Infections in Leukemia. ECIL 5: Primary antifungal prophylaxis. Available at: http:\/\/www.ecil-leukaemia.com\/telechargements2013\/ECIL5antifungalprophylaxis%2020062014Final.pdf."},{"key":"10.1016\/j.cmi.2022.01.029_bib11","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2022.01.029_bib12","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00228-016-2057-6","article-title":"Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients","volume":"72","author":"Vanstraelen","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cmi.2022.01.029_bib13","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/myc.12452","article-title":"Comparison of posaconazole serum concentrations from haematological cancer patients on posaconazole tablet and oral suspension for treatment and prevention of invasive fungal infections","volume":"59","author":"Pham","year":"2016","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2022.01.029_bib14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/0091270004271402","article-title":"Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease","volume":"45","author":"Courtney","year":"2005","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.cmi.2022.01.029_bib15","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/598327","article-title":"Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents","volume":"48","author":"Bruggemann","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.01.029_bib16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/ajh.23592","article-title":"A\u00a0conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor","volume":"89","author":"Devillier","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cmi.2022.01.029_bib17","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1086\/496927","article-title":"Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study","volume":"41","author":"Maertens","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.01.029_bib18","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1093\/annonc\/mdp596","article-title":"Citrulline-based assessment score: first choice for measuring and monitoring intestinal failure after high-dose chemotherapy","volume":"21","author":"Herbers","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cmi.2022.01.029_bib19","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/bmt.2012.278","article-title":"Citrulline and albumin as biomarkers for gastrointestinal mucositis in recipients of hematopoietic SCT","volume":"48","author":"van der Velden","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2022.01.029_bib20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jchromb.2008.12.041","article-title":"Plasma citrulline measurement using UPLC tandem mass-spectrometry to determine small intestinal enterocyte pathology","volume":"877","author":"Demacker","year":"2009","journal-title":"J\u00a0Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.cmi.2022.01.029_bib21","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s40262-016-0414-3","article-title":"A\u00a0semi-physiological population model to quantify the effect of hematocrit on everolimus pharmacokinetics and pharmacodynamics in cancer patients","volume":"55","author":"van Erp","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cmi.2022.01.029_bib22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2125.2004.02321.x","article-title":"A\u00a0semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction","volume":"59","author":"Gordi","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cmi.2022.01.029_bib23","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/bdd.2063","article-title":"Prediction of liver volume - a population-based approach to meta-analysis of paediatric, adult and geriatric populations - an update","volume":"38","author":"Small","year":"2017","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.cmi.2022.01.029_bib24","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/myc.13028","article-title":"High-dose posaconazole for azole-resistant aspergillosis and other difficult-to-treat mould infections","volume":"63","author":"Schauwvlieghe","year":"2020","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2022.01.029_bib25","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1128\/AAC.05000-14","article-title":"Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation","volume":"59","author":"Kersemaekers","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2022.01.029_bib26","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1002\/(SICI)1097-0142(19990515)85:10<2103::AID-CNCR2>3.0.CO;2-0","article-title":"Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy","volume":"85","author":"Sonis","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.cmi.2022.01.029_bib27","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/sj.bmt.1704563","article-title":"Citrulline: a potentially simple quantitative marker of intestinal epithelial damage following myeloablative therapy","volume":"34","author":"Blijlevens","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2022.01.029_bib28","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02465-17","article-title":"A\u00a0population pharmacokinetic model for a solid oral tablet formulation of posaconazole","volume":"62","author":"van Iersel","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2022.01.029_bib29","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01166-17","article-title":"Population pharmacokinetics of posaconazole tablets and Monte Carlo simulations to determine whether all patients should receive the same dose","volume":"61","author":"Petitcollin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2022.01.029_bib30","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1093\/jac\/dkw079","article-title":"Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease","volume":"71","author":"Cornely","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2022.01.029_bib31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s13054-019-2483-9","article-title":"Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients","volume":"23","author":"Sime","year":"2019","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2022.01.029_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-012-0018-5","article-title":"The clinical relevance of plasma protein binding changes","volume":"52","author":"Roberts","year":"2013","journal-title":"Clin Pharmacokinet"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X22000532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X22000532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:30:29Z","timestamp":1761118229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X22000532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1198743X22000532"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2022.01.029","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Posaconazole bioavailability of the solid oral tablet is reduced during severe intestinal mucositis","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2022.01.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}